mucosal ulceration
Recently Published Documents


TOTAL DOCUMENTS

90
(FIVE YEARS 6)

H-INDEX

19
(FIVE YEARS 0)

2021 ◽  
Vol 144 ◽  
pp. 112268
Author(s):  
Yizi Zhang ◽  
Lingli Sun ◽  
Xingfei Lai ◽  
Xingjia Peng ◽  
Shuai Wen ◽  
...  
Keyword(s):  

2021 ◽  
pp. flgastro-2021-101844
Author(s):  
Youseung Kim ◽  
Varun Kesar ◽  
David LeBel

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 2643-2643
Author(s):  
Hamzah Abu-Sbeih ◽  
Tenglong Tang ◽  
David M. Faleck ◽  
Michael L. Dougan ◽  
Anna Olsson-Brown ◽  
...  

2643 Background: Immune checkpoint inhibitor (ICI)-mediated colitis (IMC) is a common and serious adverse event. Although small series have described the clinical presentation of IMC, large multicenter series that integrate clinical, endoscopic, and histologic findings are lacking. Methods: We retrospectively assessed patients who received ICI and had endoscopically confirmed IMC from 2010 to 2019. IMC was graded based on the CTCAE version 5.0 criteria. Multivariate logistic regression analyses were conducted to assess factors associated with recurrence of IMC symptoms and long duration of corticosteroids use (> 70 days). Results: 675 patients were included. 387 patients were males (57%). Median age was 63 years. Melanoma was the most common cancer type (327; 48%). Most (365; 54%) patients received CTLA-4 inhibitor ICI, as monotherapy or in combination with PD-(L)1. Median time from ICI therapy to IMC was 62 days. IMC was grade 2 in 335 (50%) patients, Grade 3 in 181 (27%), and grade 4 in 16 (3%). 155 (23%) patients had mucosal ulceration on endoscopy, 91 of them had severe features (deep, large, or multiple ulcers); 336 (50%) patients had non-ulcerative inflammation. The rest had normal endoscopic findings with histologic inflammation. Most patients were admitted to the hospital for management of IMC (405; 60%) and 16 (3%) needed ICU-level of care. Treatment included corticosteroids in 577 (85%) patients (median duration 52 days), TNF inhibitor in 245 (36%), and vedolizumab in 90 (13%). 202 (32%) patients had recurrent IMC after resolution of symptoms. On multivariate logistic regression, factors associated with IMC recurrence and long (> 70 days) duration of corticosteroid therapy were grade of IMC ( p = 0.049), treatment with infliximab or vedolizumab ( p = 0.044), presence of mucosal ulceration ( p = 0.034 ), or features of active histologic inflammation ( p = 0.076). Of note, patients with mucosal ulceration received infliximab or vedolizumab more frequently ( p < 0.001). For patients with grade 2 IMC, mucosal inflammation on endoscopy and delay in performing endoscopy with time from IMC onset to endoscopy more than a month were associated with IMC recurrence and longer duration of corticosteroid use ( p = 0.029 and p < 0.001, respectively). 16 (3%) patients had colonic perforation, 7 of them underwent surgical resection. No IMC-related death occurred. Conclusions: IMC is a clinically significant adverse event that can lead to premature termination of ICI therapy with high rates of hospital admission. Rarely, it results in colonic perforation requiring surgical intervention and ICU admission. Our data suggest that there is a utility of endoscopic and histologic evaluation in the prediction of worse outcomes from IMC. This finding is particularly important for grade 2 IMC as current guidelines do not recommend endoscopic evaluation for this group.


2021 ◽  
Vol 2021 ◽  
pp. 1-4
Author(s):  
Manju Chandran ◽  
Wanling Zeng

Oral bisphosphonates are approved for the treatment of bone loss associated with several conditions including postmenopausal osteoporosis. Although generally well tolerated, adverse effects such as gastroesophageal reflux and oesophageal and peptic ulceration may occur. Oral mucositis and ulceration are lesser-known side effects. Proper counselling and rigorous adherence to the administration instructions are crucial. We describe a case of bisphosphonate-induced severe oral mucosal ulceration in an elderly woman that was caused by incorrect instructions and/or incorrect understanding of instructions for oral alendronate intake.


2021 ◽  
pp. 1-3
Author(s):  
Paolo Aonzo ◽  
Paolo Aonzo ◽  
Michela Ceriotti ◽  
Antonio Fernando Anania ◽  
Matteo Morena ◽  
...  

Acute abdominal pain secondary to intussusception is rare in adults and mainly caused by malignancy (70-90%), whereas in childhood intussusception’s etiology is mostly idiopathic (90% of cases). Gastrointestinal lipomas, especially in small bowel, represent an unusual cause of intussusception with complete intestinal obstruction or bleeding (acute or chronic) from mucosal ulceration. In acute settings, computed tomography (CT) should be confidently considered the gold standard for diagnosis. In adulthood, surgical management of acute symptomatic intussusception caused by lipoma is mandatory. We report a case of complete jejunal obstruction with intussusception due to 5 cm submucosal lipoma.


Author(s):  
Lucía Álvarez Santamarta ◽  
Adela Alonso Fernández-Velasco ◽  
Carmen Díaz Corte

Oral Surgery ◽  
2020 ◽  
Author(s):  
S. McLean ◽  
R. Kelly ◽  
B. Rajlawat ◽  
A. Field

2020 ◽  
Vol 38 (1) ◽  
pp. 35-41 ◽  
Author(s):  
Maria Cristina Ribeiro de Castro ◽  
Marcia Ramos-e-Silva
Keyword(s):  

2020 ◽  
Vol 9 (11) ◽  
pp. 5537
Author(s):  
Wejdan AlBander ◽  
Fahda AlDahash ◽  
Dhuha AlShamali ◽  
Raghad Bakhsh ◽  
Waad AlMadhi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document